Additional New GlycoMark® Test and SGLT-2 Inhibitor Clinical Data To Be Presented at the ADA Advancing Precision Diabetes Medicine Symposium

Tuesday, October 8, 2019 General News
Email Print This Page Comment bookmark
Font : A-A+

GlycoMark, Inc. announces additional study data describing GlycoMark® test results in patients on SGLT-2 inhibitors are being presented during the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium on October 8 - 9, 2019 in Madrid, Spain.

NEW YORK, Oct. 7, 2019 /PRNewswire-PRWeb/ -- GlycoMark, Inc. announces additional study data describing GlycoMark® test

results in patients on SGLT-2 inhibitors are being presented during the American Diabetes Association (ADA) Advancing Precision Diabetes Medicine Research Symposium on October 8 – 9, 2019 in Madrid, Spain. The GlycoMark test, an FDA-cleared and CE marked blood test used to monitor glycemic control in patients with diabetes, is sensitive and specific to detecting high blood glucose levels and glucose variability during the prior 1 to 2 weeks. These new data are in follow-up to preliminary data presented in June at the ADA 2019 Scientific Sessions in San Francisco. Those data revealed very low abnormal GlycoMark test results were correlated with patients compliant with prescribed SGLT-2 and achieved the desired effect.

The new study "GLYCOMARK 1,5-ANHYDROGLUCITOL AS A BIOMARKER OF SGLT2 INHIBITOR EFFECT" will be on display in the Madrid Marriott Auditorium Hotel and Conference Center on October 8 and attended by GlycoMark Clinical Affairs and study co-author, Jeff Dahlen, Ph.D. from 4 - 7 p.m. For interviews or to schedule a meeting with investigators or GlycoMark, please email GlycoMark@L3healthcare.com.

About the GlycoMark test The GlycoMark test quantitatively measures 1,5-anhydroglucitol (1,5-AG) from serum or plasma. The test is FDA cleared for professional use and indicated for the intermediate term monitoring of glycemic control in people with diabetes. The GlycoMark test has not been FDA cleared for monitoring SGLT-2 inhibitor effect.

About GlycoMark, Inc. GlycoMark, Inc., based in Manhattan, New York, is dedicated to improving the management and health of patients with diabetes. The company is a joint venture among Toyota Tsusho America, Inc. (New York, NY), Toyota Tsusho Corporation (Tokyo, Japan), and Nippon Kayaku Co., Ltd. (Tokyo, Japan), and is the exclusive supplier of the GlycoMark test in the U.S., Europe, Australia, the Asia-Pacific Region and the Middle East. The GlycoMark test is an FDA cleared non-fasting blood test that detects hyperglycemia and hyperglycemic excursions occurring in the prior 1 to 2 weeks. Since its discovery, the GlycoMark Test, a quantitative test for 1,5-Anhydroglucitol (1,5-AG), has been described in more than 1,300 scientific and medical publications and is shown to be independently associated with complications of diabetes. More information is available at https://www.GlycoMark.com.

GlycoMark, Inc. is the exclusive licensee of the GlycoMark test, trademark and logo.

 

SOURCE GlycoMark



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store